Identification and function probing of an antithrombin IIIβ conformation‐specific antibody. (6th January 2016)

• Record Type: Journal Article
• Authors: Jin, Y.; Yegneswaran, S.; Gu, J.‐M.; Gritzan, U.; Schönfeld, D. L.; Paz, P.; Patel, C.; Dittmer, F.; Strerath, M.; Bringmann, P.; Kauser, K.; Myles, T.; Murphy, J. E.; Hermiston, T. W.
• Is Part Of: Journal of thrombosis and haemostasis. Volume 14:Number 2(2016:Feb.)
• Page Start: 356
• Page End: 365
• Publication Date: 2016-01-06
• Subjects: antithrombin III -- blood coagulation -- endothelium -- heparin -- neutralizing antibody; Thrombosis -- Periodicals; Hemostasis -- Periodicals; Blood coagulation disorders -- Periodicals; 616.1
• DOI: 10.1111/jth.13198
• Languages: English
• ISSNs: 1538-7933

Abstract

Abstract : Essentials Antithrombin III (AT)β binds heparin with higher affinity than ATα. A conformation‐specific antibody against ATβ, TPP2009, was made to investigate ATβ in hemostasis. TPP2009 bound specifically to heparin–ATβ and greatly reduced the anticoagulant effect of AT. This antibody was effective in elucidating the importance of ATβ in hemostasis. Summary: Background: Antithrombin III (AT)β is an isoform of AT that lacks the post‐translational carbohydrate modification at Asn135. This isoform binds heparin with greater affinity than ATα, and has been shown to target antithrombotic function to the extracellular vascular endothelial injury site. Objectives: To characterize a conformation‐specific antibody against ATβ and begin to investigate the role of ATβ in maintaining hemostasis. Methods: Surface plasmon resonance (SPR), antigen binding and functional assays were conducted to characterize the mode of action of antibodies generated against heparin‐bound ATβ (ATβ*H) by the use of phage display. Results: SPR and binding studies showed that one of the antibodies, TPP2009, bound specifically to ATβ*H and glycosaminoglycan‐associated ATβ on endothelial cells. In diluted prothrombin and activated factor X (FXa)‐induced clotting assays, TPP2009 dose‐dependently reduced the anticoagulant effect of heparin in non‐hemophilic and FVIII‐deficient human plasma, with half‐maximal effective concentrations (EC50 ) of 10.5 nm and 4.7 nm, respectively. In AT‐deficient human plasma, TPP2009 dose‐dependently inhibited the effects of exogenously added ATβ and heparin. In purified systems with ATβ and pentasaccharide, TPP2009 restored > 91% of FXa activity. TPP2009 dose‐dependently reversed the effects of heparin in rabbit (EC50, 25.7 nm ) and cynomolgus monkey (EC50, 21.5 nm ) plasma, but not in mouse plasma. TPP2009 was also effective in partially restoring FXa activity in rabbit and cynomolgus monkey plasma treated with FVIII function‐neutralizing antibodies. Conclusions: TPP2009 specifically targets a unique conformational epitope on ATβ*H and blocks ATβ‐mediated anticoagulation. It effectively promotes coagulation in plasma, indicating the importance of ATβ in hemostasis.